Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the ...

Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves—insights ...

A clinical trial is launching to test the effectiveness of new tests that aim to detect genetic signatures of cancer in the ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

US patients with metastatic urothelial cancer have seen improvements in survival since ICIs and ADCs have entered the market, data suggest.

Bladder cancer is among the top 10 most common cancer types in the world, with approximately 573,000 new cases annually. Men ...

Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

Early fallopian tube cell changes were found in a high‑risk patient. A live tissue bank and organoid system will help explore initial ovarian cancer development. Very little is currently understood ...

Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled ...